PMH35 – Cost-Effectiveness of Paliperidone Palmitate Versus other Antipsychotics for the Treatment of Schizophrenia in France

A. Doutriaux, M. Cognet, S. Druais, C. Lançon (), L. Samalin, Pierre Lévy, A. Godet and P. Guillon
Additional contact information
Pierre Lévy: LEDa - Laboratoire d'Economie de Dauphine - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres, Legos - Laboratoire d'Economie et de Gestion des Organisations de Santé - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres

Post-Print from HAL

Abstract: To estimate the cost-effectiveness of paliperidone palmitate (PLAI), a once-monthly long-acting injectable (LAI) atypical antipsychotic, compared to the most common antipsychotic strategies in France.

Keywords: cost effectiveness analysis; Medical care costs; economic cost (search for similar items in EconPapers)
Date: 2014
References: Add references at CitEc
Citations:

Published in Value in Health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2014, 17 (7), ⟨10.1016/j.jval.2014.08.1268⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-01293637

DOI: 10.1016/j.jval.2014.08.1268

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().